GIULIANI, Nicola
 Distribuzione geografica
Continente #
NA - Nord America 7.379
EU - Europa 6.903
AS - Asia 3.196
Continente sconosciuto - Info sul continente non disponibili 18
AF - Africa 15
OC - Oceania 4
SA - Sud America 2
Totale 17.517
Nazione #
US - Stati Uniti d'America 7.233
CN - Cina 2.550
IE - Irlanda 1.867
SE - Svezia 1.483
FI - Finlandia 1.026
IT - Italia 668
DE - Germania 633
UA - Ucraina 621
TR - Turchia 458
AT - Austria 182
CA - Canada 144
BE - Belgio 126
GB - Regno Unito 117
IN - India 78
SG - Singapore 65
RO - Romania 64
FR - Francia 31
NL - Olanda 19
EU - Europa 18
IR - Iran 17
CZ - Repubblica Ceca 14
ES - Italia 8
HK - Hong Kong 8
BG - Bulgaria 7
IL - Israele 6
NG - Nigeria 5
RU - Federazione Russa 5
AE - Emirati Arabi Uniti 4
LU - Lussemburgo 4
PL - Polonia 4
SC - Seychelles 4
AU - Australia 3
CM - Camerun 3
DK - Danimarca 3
MD - Moldavia 3
TW - Taiwan 3
CH - Svizzera 2
HR - Croazia 2
JP - Giappone 2
KH - Cambogia 2
MA - Marocco 2
NO - Norvegia 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SM - San Marino 2
AL - Albania 1
BN - Brunei Darussalam 1
BR - Brasile 1
BZ - Belize 1
CO - Colombia 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
HU - Ungheria 1
KZ - Kazakistan 1
MX - Messico 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
Totale 17.517
Città #
Dublin 1.861
Chandler 1.645
Jacksonville 758
Beijing 626
Ashburn 571
Nanjing 406
Izmir 404
Dearborn 382
Ann Arbor 346
Princeton 323
Parma 313
San Mateo 233
Shanghai 189
Wilmington 186
Shenyang 158
New York 155
Vienna 154
Kunming 143
Nanchang 135
Brussels 126
Toronto 121
Düsseldorf 114
Helsinki 106
Hebei 105
Jinan 102
Des Moines 87
Hefei 87
Jiaxing 78
Bremen 74
Boardman 73
Tianjin 72
Seattle 63
Changsha 55
Woodbridge 54
Kocaeli 52
Hangzhou 43
Focsani 39
Pune 39
Norwalk 37
Grafing 29
Zhengzhou 28
Guangzhou 26
Houston 26
Milan 24
Fremont 21
Mestre 21
Ningbo 20
Augusta 18
Chengdu 17
Taizhou 17
Borås 16
Fairfield 16
Haikou 16
Lanzhou 15
Leawood 15
Philadelphia 15
Rockville 15
Redmond 14
Washington 14
Fuzhou 13
Cambridge 12
London 12
Timisoara 12
Wuhan 12
Chongqing 11
Modena 11
Monmouth Junction 11
Taiyuan 11
Edinburgh 10
Palermo 10
Phoenix 10
Trezzano Sul Naviglio 10
Jesi 9
Los Angeles 9
Rho 9
Amsterdam 8
Rome 8
Torino 8
Xian 8
Ahmedabad 7
Auburn Hills 7
Bologna 7
Hanover 7
Ottawa 7
Sofia 7
Central 6
Chicago 6
Madrid 6
Nerviano 6
Redwood City 6
Romainville 6
Savignano sul Rubicone 6
Southend 6
St Louis 6
Ardabil 5
Brno 5
Lagos 5
Montreal 5
Mumbai 5
Old Bridge 5
Totale 11.228
Nome #
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 115
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 102
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 97
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 97
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 96
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 96
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 94
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 94
Are the Myeloma bone microevironment cells tumoral or not? 93
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 93
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 93
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 93
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 90
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 89
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 88
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 88
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 88
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 88
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 86
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 86
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 86
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 86
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 84
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 84
A simplified sars-cov-2 pseudovirus neutralization assay 84
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 83
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 83
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 82
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 82
Possible targets to treat myeloma-related osteoclastogenesis 81
Novel targets for the treatment of relapsing multiple myeloma 81
Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking 79
Angiopoietins expression by human myeloma cells 77
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 77
Functional consequences of low activity of transport system a for neutral amino acids in human bone marrow mesenchymal stem cells 77
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 76
Oncolytic virotherapy and microenvironment in multiple myeloma 76
Analysis of lineage involvment in Philadelphia chromosome positive acute lymphoblastic leukaemia 75
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 75
Bisphosphonates inhibit IL-6 production by human osteoblast-like cells 75
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 75
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 75
Angiogenic switch in multiple myeloma patients 74
GPNA inhibits the sodium-independent transport system l for neutral amino acids 74
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma 74
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 74
Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML 74
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 73
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 73
5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men. 73
Do human myeloma cells directly produce basic FGF? 73
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 73
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 73
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation 72
Angiogenic properties of human myeloma cells: role of angiopoietin system 72
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 72
The Proteasome and Myeloma-Associated Bone Disease 72
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 72
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 71
Macrophage inflammatory protein (MIP)-3 alpha/CCL20 and its receptor CCR6 are overexpressed in the bone microenvironment and involved in osteoclast formation in multiple myeloma patients. 71
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 71
Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes 70
Angiopoietin-1 and myeloma-induced angiogenesis 70
Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo 70
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 70
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 70
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease 70
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 69
Expression and role of chemokine receptor CXCR3 in multiple myeloma 69
Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients 69
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in Multiple Myeloma patients 69
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 69
Osteopontin is produced by human multiple myeloma cells 68
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 68
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 68
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 68
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 67
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis 67
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment 66
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 66
Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis 66
Effect of residual endogenous insulin secretion on the abnormal oxytocin response to hypoglycemia in insulin-dependent diabetics. 66
Effects of hematin and Mössbauer gamma-radiation on human osteosarcoma cell lines 66
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 65
Arginine Vasopressin and Oxytocin responses to angiotensin II are mediated by AT1 receptor subtype in normal men 65
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 65
Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma 65
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 65
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 65
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 65
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 64
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 64
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 64
A translocation t(4;13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenoma 64
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 64
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 64
Beta-catenin depended and independent effects induced by myeloma cells in human and murine osteoblasts and osteoblast progenitors. 63
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 63
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 63
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 63
Totale 7.592
Categoria #
all - tutte 56.178
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.178


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019677 0 0 0 0 0 0 0 0 68 35 496 78
2019/20203.390 673 685 159 29 203 309 340 70 255 373 102 192
2020/20211.687 77 171 139 18 244 24 144 47 377 87 292 67
2021/20221.590 31 23 26 110 37 57 199 202 77 145 128 555
2022/20236.656 724 647 387 452 535 671 192 417 2.233 87 216 95
2023/20241.746 128 244 67 72 202 623 195 163 52 0 0 0
Totale 17.935